Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Ascending Single Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics / Pharmacodynamics Of PF-05280602, A Recombinant Factor VIIa Variant (813d), In Adult Hemophilia A And B Subjects With Or Without Inhibitors

X
Trial Profile

An Ascending Single Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics / Pharmacodynamics Of PF-05280602, A Recombinant Factor VIIa Variant (813d), In Adult Hemophilia A And B Subjects With Or Without Inhibitors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Marzeptacog alfa (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Catalyst Biosciences
  • Most Recent Events

    • 29 Jun 2020 According to a Catalyst Biosciences media release, data from this trial will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress being held from July 12-14, 2020.
    • 01 Aug 2019 According to a Catalyst Biosciences media release, the company plans to report data from this trial in 2020.
    • 04 Sep 2018 Results presented in the Catalyst Biosciences media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top